BioSpecifics Technologies Corp. Stock Price and Value Analysis

Should you buy BioSpecifics Technologies Corp. stock? (NasdaqGM:BSTC). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

BSTC Free Cash Flow Trend

Hmm, we can't give any reliable projection for BioSpecifics Technologies Corp.'s growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for BSTC
Free Cash Flow trendline for BioSpecifics Technologies Corp.

Inside the BSTC Numbers

BSTC Price
(BioSpecifics Technologies Corp. stock price per share)
[?] PE Ratio versus Sector 30% higher than other Healthcare stocks
[?] PE Ratio versus Industry 54% lower than other Biotechnology stocks
[?] Cash Yield 0.74%
[?] Free Cash Flow Jitter 41%

Is BioSpecifics Technologies Corp. Stock on Sale?

Based on our analysis, we believe that you should not buy BioSpecifics Technologies Corp. right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BSTC Stock?

Does BioSpecifics Technologies Corp. have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.